Supreme Court Decision Allows for Compensation

A March 4th Supreme Court decision has allowed juries to award damages for the harmful side effects of drugs, even if the drug had the proper FDA approved warning labels. This ruling comes in the wake of recent discovery that many drugs widely used on the market over the past decade were the result of falsified medical research.Thousands of cases against the makers of drugs like Vioxx, will now have a higher probabilty of settling, after the drug has been shown to cause serious heart related problems, as well as hinder bone growth. If you or a loved one has had their quality of life decline due to the harmful side effects of a prescription … [Read more...]

Lessons Learned From Vioxx: Why Trasylol and Heparin Victims Must File Suit To Ensure Honest Marketing and Safer Drug Products

Byron Richards from medicationresources.com has written a very interesting post entitled, "Vioxx Shocker-Merck Wrote Many Of the Published Studies." Needless to say, he had me at hello on this one. After a few weeks of researching the cover-ups and shoddy scientific testing of dangerous drugs such as Heparin and Trasylol, this post solidified in my mind why it is so important for victims of these drugs to come forward and file suit. Richards reports: The lawsuits over Vioxx have forced very uncomfortable documents into public view, exposing that Big Pharma has massively corrupted the scientific database with what amounts to promo pieces … [Read more...]

Heart Risk Falls When Patients Stop Taking Vioxx

There's good news for Vioxx patients. It seems that cardiovascular risks decline when patients stop taking the drug. Merck continued its 3 year Vioxx study for a 4th year. Those fourth-year results, as analyzed by Merck and released yesterday, showed that former Vioxx and placebo users reported a nearly similar rate of cardiovascular events. Among 2,178 patients, 28 formerly on Vioxx and 16 formerly on placebo suffered confirmed thrombotic cardiovascular events. An undisclosed number died. Peter S. Kim, head of West Point-based Merck Research Laboratories, said the 28-to-16 difference is not statistically significant and might be due … [Read more...]